Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
According to the recently published report 'Leucine Rich Repeat Serine Threonine Protein Kinase 2 - Drugs In Development, 2022'; Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes.
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system.
The report 'Leucine Rich Repeat Serine Threonine Protein Kinase 2 - Drugs In Development, 2022' outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 13 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Oncology and Ophthalmology which include indications Parkinson's Disease, Amyotrophic Lateral Sclerosis, Crohn's Disease (Regional Enteritis), Glioblastoma Multiforme (GBM), Ocular Hypertension, Open-Angle Glaucoma, Pancreatic Cancer, Pulmonary Hypertension, Triple-Negative Breast Cancer (TNBC) and Unspecified Neurologic Disorders.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Leucine Rich Repeat Serine Threonine Protein Kinase 2 - Drugs In Development, 2022'; Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes.
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system.
The report 'Leucine Rich Repeat Serine Threonine Protein Kinase 2 - Drugs In Development, 2022' outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 13 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Oncology and Ophthalmology which include indications Parkinson's Disease, Amyotrophic Lateral Sclerosis, Crohn's Disease (Regional Enteritis), Glioblastoma Multiforme (GBM), Ocular Hypertension, Open-Angle Glaucoma, Pancreatic Cancer, Pulmonary Hypertension, Triple-Negative Breast Cancer (TNBC) and Unspecified Neurologic Disorders.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
- The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Overview
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
1st Bio Therapeutics Inc
Arrien Pharmaceuticals LLC
Blue Therapeutics Inc
Cerevel Therapeutics Holdings Inc
D. Western Therapeutics Institute Inc
Denali Therapeutics Inc
E-scape Bio Inc
Guangzhou DM Intelligence Ltd
H. Lundbeck AS
Halia Therapeutics Inc
ICB International Inc
Imago Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Lead Discovery Center GmbH
Merck & Co Inc
Neuron23 Inc
Oncodesign SA
Shape Therapeutics Inc
Voronoi Group
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Drug Profiles
Antibody 1 to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Antibody to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
ARN-1104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DNL-151 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DNL-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DNL-975 - Drug Profile
Product Description
Mechanism Of Action
Drug to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Drug to Inhibit LRRK2 for Unspecified Neurologic Disorders - Drug Profile
Product Description
Mechanism Of Action
ESB-5070 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FB-418 - Drug Profile
Product Description
Mechanism Of Action
GNE-7915 - Drug Profile
Product Description
Mechanism Of Action
History of Events
H-1337 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ION-859 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NEU-723 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ODS-2005294 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PF-06447475 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SHP-202 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
VRN-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Dormant Products
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Jun 14, 2021: Servier and Oncodesign announce the selection of a preclinical candidate as part of their collaboration targeting new treatments for Parkinson’s Disease
May 01, 2021: Phase 1b studies of its LRRK2 inhibitor, BIIB122/DNL151, supporting late-stage development plans in Parkinson’s Disease
Aug 06, 2020: Biogen and Denali to collaborate on LRRK2 program for Parkinson’s Disease and certain tv platform-enabled programs for neurodegenerative diseases
Aug 06, 2020: Denali Therapeutics announces decision to advance DNL151 into late stage clinical studies in Parkinson’s Patients
Feb 17, 2020: Oncodesign and Servier reach a key first milestone in their strategic partnership on LRRK2 inhibitors for Parkinson’s Disease
Sep 05, 2019: Denali begins dosing Parkinson’s patients in Phase Ib trial
Sep 04, 2019: GeoVax announces publication of Lassa Fever Vaccine study results
Sep 04, 2019: BioXcel Therapeutics receives FDA Orphan Drug Designation for BXCL701 for the treatment of Acute Myeloid Leukemia (AML)
Dec 10, 2018: Denali Therapeutics announces first patient dosed in phase 1b study of DNL201 for parkinson's disease
Aug 01, 2018: Denali Therapeutics announces positive clinical results from LRRK2 inhibitor program for parkinsons disease
Apr 05, 2018: Allysta Pharmaceuticals Doses First Patient in Phase 2A Study in Glaucoma
Dec 20, 2017: Denali Therapeutics Provides Update on DNL151
Dec 20, 2017: Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson's Disease
May 23, 2017: Origenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of Neurodegenerative and Inflammatory Diseases
May 30, 2016: Oncodesign is granted new patent protecting key molecules generated from its Nanocyclix technology platform for next generation kinase inhibitors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Overview
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
1st Bio Therapeutics Inc
Arrien Pharmaceuticals LLC
Blue Therapeutics Inc
Cerevel Therapeutics Holdings Inc
D. Western Therapeutics Institute Inc
Denali Therapeutics Inc
E-scape Bio Inc
Guangzhou DM Intelligence Ltd
H. Lundbeck AS
Halia Therapeutics Inc
ICB International Inc
Imago Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Lead Discovery Center GmbH
Merck & Co Inc
Neuron23 Inc
Oncodesign SA
Shape Therapeutics Inc
Voronoi Group
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Drug Profiles
Antibody 1 to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Antibody to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
ARN-1104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DNL-151 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DNL-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DNL-975 - Drug Profile
Product Description
Mechanism Of Action
Drug to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Drug to Inhibit LRRK2 for Unspecified Neurologic Disorders - Drug Profile
Product Description
Mechanism Of Action
ESB-5070 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FB-418 - Drug Profile
Product Description
Mechanism Of Action
GNE-7915 - Drug Profile
Product Description
Mechanism Of Action
History of Events
H-1337 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ION-859 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NEU-723 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ODS-2005294 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PF-06447475 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SHP-202 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
VRN-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Dormant Products
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Jun 14, 2021: Servier and Oncodesign announce the selection of a preclinical candidate as part of their collaboration targeting new treatments for Parkinson’s Disease
May 01, 2021: Phase 1b studies of its LRRK2 inhibitor, BIIB122/DNL151, supporting late-stage development plans in Parkinson’s Disease
Aug 06, 2020: Biogen and Denali to collaborate on LRRK2 program for Parkinson’s Disease and certain tv platform-enabled programs for neurodegenerative diseases
Aug 06, 2020: Denali Therapeutics announces decision to advance DNL151 into late stage clinical studies in Parkinson’s Patients
Feb 17, 2020: Oncodesign and Servier reach a key first milestone in their strategic partnership on LRRK2 inhibitors for Parkinson’s Disease
Sep 05, 2019: Denali begins dosing Parkinson’s patients in Phase Ib trial
Sep 04, 2019: GeoVax announces publication of Lassa Fever Vaccine study results
Sep 04, 2019: BioXcel Therapeutics receives FDA Orphan Drug Designation for BXCL701 for the treatment of Acute Myeloid Leukemia (AML)
Dec 10, 2018: Denali Therapeutics announces first patient dosed in phase 1b study of DNL201 for parkinson's disease
Aug 01, 2018: Denali Therapeutics announces positive clinical results from LRRK2 inhibitor program for parkinsons disease
Apr 05, 2018: Allysta Pharmaceuticals Doses First Patient in Phase 2A Study in Glaucoma
Dec 20, 2017: Denali Therapeutics Provides Update on DNL151
Dec 20, 2017: Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson's Disease
May 23, 2017: Origenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of Neurodegenerative and Inflammatory Diseases
May 30, 2016: Oncodesign is granted new patent protecting key molecules generated from its Nanocyclix technology platform for next generation kinase inhibitors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 1st Bio Therapeutics Inc, 2022
Pipeline by Arrien Pharmaceuticals LLC, 2022
Pipeline by Blue Therapeutics Inc, 2022
Pipeline by Cerevel Therapeutics Holdings Inc, 2022
Pipeline by D. Western Therapeutics Institute Inc, 2022
Pipeline by Denali Therapeutics Inc, 2022
Pipeline by E-scape Bio Inc, 2022
Pipeline by Guangzhou DM Intelligence Ltd, 2022
Pipeline by H. Lundbeck AS, 2022
Pipeline by Halia Therapeutics Inc, 2022
Pipeline by ICB International Inc, 2022
Pipeline by Imago Pharmaceuticals Inc, 2022
Pipeline by Ionis Pharmaceuticals Inc, 2022
Pipeline by Lead Discovery Center GmbH, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Neuron23 Inc, 2022
Pipeline by Oncodesign SA, 2022
Pipeline by Shape Therapeutics Inc, 2022
Pipeline by Voronoi Group, 2022
Dormant Projects, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 1st Bio Therapeutics Inc, 2022
Pipeline by Arrien Pharmaceuticals LLC, 2022
Pipeline by Blue Therapeutics Inc, 2022
Pipeline by Cerevel Therapeutics Holdings Inc, 2022
Pipeline by D. Western Therapeutics Institute Inc, 2022
Pipeline by Denali Therapeutics Inc, 2022
Pipeline by E-scape Bio Inc, 2022
Pipeline by Guangzhou DM Intelligence Ltd, 2022
Pipeline by H. Lundbeck AS, 2022
Pipeline by Halia Therapeutics Inc, 2022
Pipeline by ICB International Inc, 2022
Pipeline by Imago Pharmaceuticals Inc, 2022
Pipeline by Ionis Pharmaceuticals Inc, 2022
Pipeline by Lead Discovery Center GmbH, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Neuron23 Inc, 2022
Pipeline by Oncodesign SA, 2022
Pipeline by Shape Therapeutics Inc, 2022
Pipeline by Voronoi Group, 2022
Dormant Projects, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
